Liver enzymes but not free fatty acid levels predict markers of insulin sensitivity in overweight and obese, nondiabetic adults

Nutrition Research

Volumn 33, Issue 10, 2013, Pages 781-788

  Gray, Belinda ^a   Muhlhausler, Beverly Sara ^b   Davies, Peter Stephen Wynford ^a   Vitetta, Luis ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Human; Insulin; Liver; N 3 Fatty acids; N 6 Fatty acids; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CHOLESTEROL; DOCOSAHEXAENOIC ACID; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; INSULIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SATURATED FATTY ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIETARY INTAKE; DISEASE ASSOCIATION; FATIGUE; FATTY ACID BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE;

ALANINE TRANSAMINASE; ALT; ASPARTATE TRANSAMINASE; AST; BMI; BODY MASS INDEX; COEFFICIENTS OF VARIATION; CV; DHA; DOCOSAHEXAENOIC ACID; EGFR; EICOSAPENTAENOIC ACID; EPA; ESTIMATED GLOMERULAR FILTRATION RATE; FFAS; FREE FATTY ACIDS; GGT; HOMA; HOMEOSTASIS MODEL OF ASSESSMENT; HUMAN; ICAM-1; INSULIN; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE 1; IR; LDL; LIVER; LOW-DENSITY LIPOPROTEIN; N-3 FATTY ACIDS; N-6 FATTY ACIDS; NATIONAL GLYCOHEMOGLOBIN STANDARDIZATION PROGRAM; NQSP; OBESITY; POLYUNSATURATED FATTY ACIDS; PUFA; R; SPEARMAN CORRELATION COEFFICIENTS; T2DM; TYPE 2 DIABETES MELLITUS; WAIST CIRCUMFERENCE; WAIST-TO-HEIGHT RATIO; WC; WHTR; Γ-GLUTAMYL TRANSPEPTIDASE;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS; EXERCISE; FATIGUE; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; OBESITY; OBESITY, ABDOMINAL; OVERWEIGHT; PHOSPHOLIPIDS; REFERENCE VALUES;

EID: 84884590312     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2013.07.019     Document Type: Article

References (51)

1. Kahn B., Flier J. Obesity and insulin resistance. Clin Invest 2000, 106(4):473-481.
2. Smith S., Ravussin E. Emerging paradigms for understanding fatness and diabetes risk. Curr Diab Rep 2002, 2:223-230.
3. Rande P., Garland P., Hales C., Newsholme E. The glucose-fatty acid cycle, its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
4. Robertson R., Harmon J., Tran P., Poitout V. β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl 1):S119-S124.
5. Yki-Jarvinen H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc Med 2002, 95:39-45.
6. Chaldakov G., Stankulov I., Hristova M., Ghenev P. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des 2003, 9:1023-1031.
7. Kahn S. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
8. WHO Diabetes: Fact Sheet No 312 2012, World Health Organisation, Geneva.
9. Duncan K., Bacon I., Weinsier R. The effects of high and low energy density diets on satiety, energy intake, and eating time of obese and nonobese subjects. Am J Clin Nutr 1983, 37(763-7).
10. Rolls B., Drewnowski A., Ledikwe J. Changing the energy density of the diet as a strategy for weight management. J Am Diet Assoc 2005, 105:S98-S103.
11. Simopoulos A. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999, 70(Suppl):S560-S569.
12. Micallef M., Munro I., Phang M., Garg M. Plasma n-3 polyunsaturated fatty acids are negatively associated with obesity. Brit J Nutr 2009, 102:1370-1374.
13. Janczyk W., Socha P., Lebensztejn D., Wierzbicka A., Mazur A., Neuhoff-Murawska J., et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr 2013, 13:85-95.
14. Tu W., Cook-Johnson R., James M., Mühlhäusler B., Gibson R. Omega-3 long chain fatty acid synthesis is regulated more by substrate levels than gene expression. Prostaglandins Leukot Essent Fatty Acids 2010 Aug, 83(2):61-68.
15. Valenzuelaa R., Videla L. The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. Food Funct 2011, 2:644-648.
16. Araya J., Rodrigo R., Videla L., Thielemann L., Orellana M., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004, 106:635-643.
17. Lim W., Hong S., Nelesen R., Dimsdale J. The association of obesity, cytokine levels, and depressive symptoms with diverse measures of fatigue in healthy subjects. Arch Intern Med 2005, 165:910-915.
18. Lloyd C., Orchard T. Physical and psychological well-being in adults with type 1 diabetes. Diabetes Res Clin Pract 1999, 44:9-19.
19. Vgontzas A., Bixler E., Chrousos G. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann N Y Acad Sci 2006, 1083:329-344.
20. Elimimian J., Smith P., Iluore A. Musculoskeletal disorders and the consumption of disability products. Health Mark Q 1999, 17:83-98.
21. Resnick H., Carter E., Aloia M., Phillips B. Cross-sectional relationship of reported fatigue to obesity, diet, and physical activity: results from the third national health and nutrition examination survey. J Clin Sleep Med 2006, 2(2):163-169.
22. Kelly T., Yang W., Chen C., Reynolds K., He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008, 32:1431-1437.
23. WHO. BMI Classification Geneva: World Health Organisation; 2006 [cited 2010 May 9]. Available at:. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
24. Wallace T., Levy J., Matthews D. Use and abuse of HOMA modeling. Diabetes Care 2004, 27(6):1487-1495.
25. Schroder H., Covas M., Marrugat J., Vila J., Pena A., Alcantra M., et al. Use of a three-day estimated food record, a 72-hour recall and a food-frequency questionnaire for dietary assessment in a Mediterranean Spanish population. Clin Nutr 2001, 20(5):429-437.
26. Booth M. Assessment of physical activity: an international perspective. Res Q Exerc Sport 2000, 71(2):s114-s120.
27. Tehard B. Comparison of two physical activity questionnaires in obese subjects: the NUGENOB study. Med Sci Sports Exerc 2005, 37:1535-1541.
28. Hagstromer M., Oja P., Sjostrom M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr 2006, 9:755-762.
29. Fisk J., Ritvo P., Ross L., Haase D., Marrie T.J., Schlech W., et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994, 18:s79-s83.
30. Schipper H., de Jager W., van Dijk M., Meerding J., Zelissen P., Adan R., et al. A multiplex immunoassay for human adipokine profiling. Clin Chem 2010, 56(8):1320-1328.
31. Pfleger C., Schloot N., ter Veld F. Effect of serum content and diluent selection on assay sensitivity and signal intensity in multiplex bead-based immunoassays. J Immunol Methods 2007, 329:214-218.
32. R&D Systems Human Obesity MultiAnalyte Profiling Base Kit Minneapolis2012 [06/02/2012] Available from:. http://www.rndsystems.com/pdf/LOB000.pdf.
33. Loo B., Marniemi J. Evaluation of multiplex immunoassays, used for determination of adiponectin, resistin, leptin, and ghrelin from human blood samples, in comparison to ELISA assay. Scand J Clin Lab Invest 2011, 71(3):221-226.
34. Diagnostics Wako HR Series NEFA-HR(2) Japan: Wako Diagnostics; 2008 [cited 2013 July 9] Available from:. http://www.wakodiagnostics.com/r_nefa.html.
35. Pouliot M., Despres J., Lemieux S., et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994, 73:460-468.
36. Michael M., Kulkarni R., Postic C., Previs S., Shulman G., Magnuson M., et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000, 6:87-97.
37. Perseghin G., Mazzaferro V., Sereni L., Regalia E., Benedini S., Bazzigaluppi E., et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 2000, 31(3):694-703.
38. Grundy S. Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol 2007, 27:4-7.
39. Yamada J., Tomiyama H., Yambe M., Koji Y., Motobe K., Shiina K., et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis 2006, 189:198-205.
40. Ohlson L., Larsson B., Bjorntorp P., Eriksson H., Svardsudd K., Welin L., et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988, 31:798-805.
41. Perry I., Wannamethee S., Shaper A. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998, 21:732-737.
42. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257(1):79-83. PubMed PMID: 10092513. [Epub 1999/03/27. eng.].
43. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
44. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
45. Fargnoli J., Sun Q., Olenczuk D., Qi L., Zhu Y., Hu F., et al. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010, 162:281-288.
46. Kim M., Namkoong C., Kim H., Jang P., Kim Pak Y., Katakami H., et al. Chronic central administration of ghrelin reverses the effects of leptin. Int J Obes 2004, 28:1264-1271.
47. Loffreda S., Yang S., Lin H., Karp C., Brengman M., Wang D., et al. Leptin regulates proinflammatory immune responses. FASEB J 1998, (1):57-65. [PubMed PMID: 9438411].
48. Itoh M., Suganami T., Satoh N., Tanimoto-Koyama K., Yuan X., Tanaka M., et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Am Heart Association J 2007, 27:1918-1925. [English].
49. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
50. Guilherme A., Virbasius J., Puri V., Czech M. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9:367-377.
51. Hewlett S., Hehir M., Kirwanm J. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 2007, 57:429-439.